	Early outcomes after focal high-dose-rate brachytherapy in low- and favorable intermediate-risk prostate cancer: promising early results from a prospective randomized trial. Open Med (Wars) Jonusas J, Patasius A, Trakymas M, Akelaitis K, Dziugelis M, Burkanas M, Venius J, Smailyte G, Kincius M. PMID: 42519814 [PubMed - as supplied by publisher]
	Research progress in metabolic reprogramming and targeting metabolic pathways for clear cell renal cell carcinoma. Genes Dis Yao JT, Hu PC, Li XW, Xu JC, Wang KJ, Ye SZ, Meng XY, Chen HC, Liang Y, Ma Q. PMID: 42519728 [PubMed - as supplied by publisher]
	Real-world implementation of a pre-consultation patient educational tool for intermediate risk prostate cancer. Clin Transl Radiat Oncol Borras-Osorio M, Kowalchuk RO, Preston HR, Rajkumar AW, Uptmor AM, Davis BJ, Choo CR, Stish BJ, Phillips RM, Malouff TD, Traughber BJ, Wilson J, Lozko Y, Mastroleo F, Namazi MJ, Routman DM, Ebner DK, Waddle MR. PMID: 42519504 [PubMed - as supplied by publisher]
	Factors associated with help-seeking for urinary symptoms among Chinese patients with bladder cancer: A qualitative study. Asia Pac J Oncol Nurs Wang B, Zou J, Gao L, Lou F, Qi Z, Dai Y. PMID: 42519177 [PubMed - as supplied by publisher]
	Incremental diagnostic value of MRI PI-RADS classification combined with PSA density for prostate cancer. Front Oncol Sun X, Chen Y, Ling S, Gong S, Liu B. PMID: 42518805 [PubMed - as supplied by publisher]
	Perioperative therapy in muscle-invasive bladder cancer: real-world evidence from the MINOTAURO study. ESMO Real World Data Digit Oncol Lainez N, Martínez-Kareaga M, Sagastibeltza-Marinalarena N, Sánchez M, Díaz de Cerio A, Sánchez-Escribano R, Sotelo M, Torre S, Calderero V, Verdún JA, Gil-Arnáiz I, Menéndez M, Moreno A, de Ávila L, Fernández R, Trincado P, Peláez M, Anido U, Climent MÁ, Durán I. PMID: 42518717 [PubMed - as supplied by publisher]
	Comparative Evaluation of AI Chatbots for Testicular Cancer Education: Validity, Information Quality, and Readability. Ann Surg Oncol Zhao J, Sun S, Zhao A, Liang R, Peng L, Peng X, Li R. PMID: 42518148 [PubMed - as supplied by publisher]
	Surgical Management of PSMA PET-Positive Lymph Nodes in Prostate Cancer. Curr Urol Rep Cosenza A, Quarta L, Galdieri A, Brancaccio M, Occhi A, Porzi ME, Zaurito P, Viti A, Santangelo A, Scilipoti P, Scuderi S, Barletta F, Stabile A, Montorsi F, Briganti A, Gandaglia G. PMID: 42518100 [PubMed - as supplied by publisher]
	Impact of central review and MRI image quality on prostate cancer diagnosis and biopsy decision-making in referred patients. Abdom Radiol (NY) Zheng Z, Liu Y, Wu S, Chen Y, Jin P, Shi L, Zhang G, Sun H, Wang X, Xu L. PMID: 42517901 [PubMed - as supplied by publisher]
	Use of whole-body MRI to evaluate residual tumour burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer. Br J Radiol Thompson C, Withey SJ, Tunariu N, Parker C, Tree A, Reid A, Pathmanathan A, Murray J. PMID: 42517815 [PubMed - as supplied by publisher]
	Erratum for: (61)Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of (61)Cu-labeled PET Radiotracers. Radiology Ulaner GA, Bassett JC, Reddy R, Thomsen B, Reynolds D, Jerjian KJ, Wolfe R, Benjamin DJ, Fani M, O'Donoghue J, Baier M, Schubert N, Pais B, De Rose F, Jaafar L. PMID: 42517773 [PubMed - as supplied by publisher]
	Combination of Radiation Therapy and Irreversible Electroporation for Intermediate-Risk Prostate Cancer (RTIRE): A Phase 1 Trial. Radiology McClure TD, Wang S, Ballman KV, Diven M, Osborne JR, O'Dwyer E, Piscopo J, Khani F, Marciscano A, Al Hussein Al Awamlh B, Barbieri C, Nagar H. PMID: 42517770 [PubMed - as supplied by publisher]
	Tumor-associated macrophages and lineage plasticity in prostate cancer: from established myeloid programs to emerging spatial hypotheses. Front Immunol Li J, Li J, Zhao Y, Yu Y, Cui X. PMID: 42516385 [PubMed - as supplied by publisher]
	Innovations in Diagnosis Immunotherapy and Combination Therapy of Prostate Cancer: A Patent-driven Analysis. Recent Pat Anticancer Drug Discov Relan R, Sambar B, Dudam AK, Kanugo A. PMID: 42515880 [PubMed - as supplied by publisher]
	INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol. BJU Int Lister-Whelan R, Senior E, Kendall J, Oughton JB, Collinson F, Griffin J, Hubbard R, Kennish S, Noon A, Rosario DJ, Riaz IB, Telliez J, Catto JWF, Hussain SA. PMID: 42515859 [PubMed - as supplied by publisher]
	Preclinical Models of Bladder Cancer: Barrier, Metabolic, and Translational Susceptibility. Pharmaceuticals (Basel) Liu T, Li W, Yin Q, Liu D, Wang Y, Cui N. PMID: 42515797 [PubMed - as supplied by publisher]
	Feasibility and Acceptability of a Group-Based Telehealth Stress Management and Resilience Training Intervention for Men with Prostate Cancer on Active Surveillance. J Clin Med Mohamed NE, Noel JC, Scharp D, Fu W, Joshi H, Korn T, Johnson I, Tewari A, Gonzalez A. PMID: 42513453 [PubMed - as supplied by publisher]
	CT-Based Radiomics for Prediction of Molecular Markers in Clear Cell Renal Cell Carcinoma: A Comprehensive Review. Medicina (Kaunas) Boukali E, Koumpis P, Romeo E, Vartholomatos E, Alexiou GA, Argyropoulou MI, Tsili AC. PMID: 42512891 [PubMed - as supplied by publisher]
	Theranostic Potential of (177)Lu-TLX591 with Best Standard-of-Care and (68)Ga-PSMA-11 PET for Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the Phase 1 ProstACT SELECT Trial. Cancers (Basel) Lenzo N, O'Byrne K, Ngai S, Krieger L, Wong V, Cade DN. PMID: 42512394 [PubMed]
	Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review. Cancers (Basel) Sala-González N, Chekhun S, Fina C, Vilaseca M, Rossylna O, Boix R, Bella-Burgos B, Comet J. PMID: 42512334 [PubMed - as supplied by publisher]

Articles 1 - 20 / 180347

Page 1 of 9018



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy